FY2025 EPS Estimates for AbbVie Inc. (NYSE:ABBV) Lowered by Analyst

AbbVie Inc. (NYSE:ABBV) – Investment analysts at William Blair dropped their FY2025 EPS estimates for shares of AbbVie in a report released on Wednesday, April 17th. William Blair analyst T. Lugo now forecasts that the company will post earnings per share of $11.86 for the year, down from their previous estimate of $12.27. William Blair has a “Outperform” rating on the stock. The consensus estimate for AbbVie’s current full-year earnings is $11.18 per share.

Other research analysts have also issued research reports about the stock. BMO Capital Markets lifted their price target on shares of AbbVie from $187.00 to $195.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Truist Financial boosted their price objective on shares of AbbVie from $180.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 6th. Barclays boosted their price objective on shares of AbbVie from $185.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 27th. Guggenheim boosted their price objective on shares of AbbVie from $188.00 to $190.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd. Finally, Raymond James boosted their price objective on shares of AbbVie from $181.00 to $189.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Three research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $177.43.

AbbVie Stock Performance

Shares of ABBV opened at $166.42 on Thursday. The company has a debt-to-equity ratio of 5.02, a quick ratio of 0.76 and a current ratio of 0.87. AbbVie has a twelve month low of $130.96 and a twelve month high of $182.89. The firm’s 50 day moving average price is $175.44 and its two-hundred day moving average price is $160.10. The firm has a market cap of $294.67 billion, a P/E ratio of 60.96, a PEG ratio of 2.11 and a beta of 0.58.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, February 2nd. The company reported $2.79 EPS for the quarter, topping the consensus estimate of $2.76 by $0.03. AbbVie had a net margin of 8.95% and a return on equity of 162.28%. The company had revenue of $14.30 billion during the quarter, compared to analysts’ expectations of $14.02 billion. During the same quarter in the previous year, the company earned $3.60 EPS. AbbVie’s revenue was down 5.4% on a year-over-year basis.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ABBV. Maryland State Retirement & Pension System boosted its position in shares of AbbVie by 0.6% during the 1st quarter. Maryland State Retirement & Pension System now owns 138,163 shares of the company’s stock valued at $25,159,000 after acquiring an additional 774 shares during the last quarter. FORVIS Wealth Advisors LLC boosted its stake in AbbVie by 7.9% in the first quarter. FORVIS Wealth Advisors LLC now owns 16,665 shares of the company’s stock worth $3,035,000 after buying an additional 1,223 shares in the last quarter. Marshall Financial Group LLC boosted its stake in AbbVie by 5.6% in the first quarter. Marshall Financial Group LLC now owns 10,465 shares of the company’s stock worth $1,906,000 after buying an additional 558 shares in the last quarter. American National Bank & Trust Co. VA purchased a new stake in AbbVie in the first quarter worth approximately $10,194,000. Finally, FCG Investment Co purchased a new stake in AbbVie in the first quarter worth approximately $1,413,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling at AbbVie

In other news, CEO Richard A. Gonzalez sold 138,616 shares of the firm’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $177.27, for a total transaction of $24,572,458.32. Following the completion of the sale, the chief executive officer now directly owns 519,099 shares of the company’s stock, valued at approximately $92,020,679.73. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CFO Scott T. Reents sold 14,140 shares of AbbVie stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $177.44, for a total value of $2,509,001.60. Following the completion of the sale, the chief financial officer now owns 27,065 shares of the company’s stock, valued at approximately $4,802,413.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Richard A. Gonzalez sold 138,616 shares of AbbVie stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $177.27, for a total value of $24,572,458.32. Following the completion of the sale, the chief executive officer now directly owns 519,099 shares of the company’s stock, valued at approximately $92,020,679.73. The disclosure for this sale can be found here. In the last three months, insiders have sold 383,324 shares of company stock worth $67,780,003. Corporate insiders own 0.25% of the company’s stock.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be paid a dividend of $1.55 per share. This represents a $6.20 annualized dividend and a yield of 3.73%. The ex-dividend date is Friday, April 12th. AbbVie’s dividend payout ratio (DPR) is presently 227.11%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.